Inc. 22 Cherry Hill Drive Danvers
24 hours a day, 7 days a week 1.800.422.8666
U.S. Field Service: 978.646.1700
European Emergencies: +49.0.1805.2246633
Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. CEO, Chairman, and President Michael R. Minogue has focused the company’s efforts on developing ground-breaking technologies designed to improve the patient outcomes focused on native heart recovery. Founded in 1981 for the purpose of developing the world’s first artificial heart, Abiomed has remained dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
IAbiomed was founded in Danvers by David M. Lederman in 1981 as Applied Biomedical Corporation, and began working on the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, implanting the first artificial heart into a Kentucky man in July 2001. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.
In 2004, Michael R. Minogue became president and CEO of Abiomed. In 2005, Abiomed purchased ventricular assist device company Impella CardioSystems AG of Aachen, Germany, maker of the Impella heart pump, developed by Thorsten Siess, who is now the Chief Technology Officer at Abiomed.
Since 2005, Impella heart devices have received a series of FDA approvals.
In 2007, the Impella 2.5 heart pump was among 35 healthcare products to receive a 2007 Medical Design Excellence Award.
Minogue helped found the Medical Technology Veterans Program (MVP), a career training and mentorship initiative designed to help veterans entering the civilian workforce transition into jobs in the medical device and life sciences industries. He currently serves as chairman of the program.
Impella heart pumps ventricular assist devices for high-risk PCI procedures
While Abiomed was founded in 1981, it received its first pre-market approval from the FDA only in March 2015. Impella 2.5 was approved for use during elective and high-risk percutaneous coronary intervention or PCI procedure in the USA. And this is how, this small company launched a smallest heart pump in the market, capable of restoring the ability of the patient’s native heart to pump blood.
Most often, patients undergoing PCI procedure suffer from coronary artery disease, where there is buildup of plaque in coronary arteries causing restricted blood and oxygen supply to the heart muscle. This can ultimately result in heart failure, where the heart is unable to pump sufficient blood. Around 900,000 patients fall prey to coronary artery disease annually in the U.S. Interventionnal cardiologist may use the Impella for high risk PCI.